Montermoso Saira, Eilers Grant, Allen Audrey, Sharp Robert, Hwang Young, Bushman Frederic D, Gupta Kushol, Duyne Gregory Van
Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States; Graduate Group in Biochemistry, Biophysics, and Chemical Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
J Mol Biol. 2025 May 21;437(17):169224. doi: 10.1016/j.jmb.2025.169224.
HIV-1 integrase (IN) is targeted by two classes of antivirals: integrase strand transfer inhibitors (INSTIs), which bind to the active site within the catalytic core domain (CCD), and allosteric integrase inhibitors (ALLINIs), which bind at the CCD dimer interface. ALLINIs were initially designed to disrupt interactions with the cellular cofactor LEDGF/p75, but it has become clear that ALLINIs primarily act by promoting formation of aberrant integrase polymers. The ALLINIs achieve this by stabilizing ectopic intermolecular interactions between the CCD dimer and the integrase carboxy-terminal domain (CTD), which disrupts viral maturation. Previously, we determined the structure of full-length HIV-1 IN bound to the ALLINI GSK1264 at 4.4 Å resolution, revealing its polymerization mechanism. More recently, we reported the X-ray crystal structure of a minimal ternary complex between CCD, CTD, and the ALLINI BI-224436 at a higher resolution. In this study, we improve the original 4.4 Å structure using this higher-resolution information and report two new structures of full-length HIV-1 IN harboring escape mutations in the CCD (Trp131Cys) or CTD (Asn222Lys) bound with the prototype ALLINI BI-D at 4.5 Å. These structures reveal perturbations to the tertiary organization associated with escape substitutions, which correlate with their reduced ability to form ectopic ALLINI-induced polymers in vitro. These findings suggest a general structural mechanism of ALLINI resistance and provide insights for the design of improved ALLINIs.
HIV-1整合酶(IN)是两类抗病毒药物的作用靶点:整合酶链转移抑制剂(INSTIs),其与催化核心结构域(CCD)内的活性位点结合;变构整合酶抑制剂(ALLINIs),其在CCD二聚体界面结合。ALLINIs最初设计用于破坏与细胞辅因子LEDGF/p75的相互作用,但现在已经明确,ALLINIs主要通过促进异常整合酶聚合物的形成起作用。ALLINIs通过稳定CCD二聚体与整合酶羧基末端结构域(CTD)之间的异位分子间相互作用来实现这一点,这会破坏病毒成熟。此前,我们以4.4 Å分辨率确定了与ALLINI GSK1264结合的全长HIV-1 IN的结构,揭示了其聚合机制。最近,我们报道了CCD、CTD与ALLINI BI-224436之间最小三元复合物的更高分辨率X射线晶体结构。在本研究中,我们利用这一更高分辨率信息改进了原始的4.4 Å结构,并报道了全长HIV-1 IN的两个新结构,其在CCD(Trp131Cys)或CTD(Asn222Lys)中存在逃逸突变,与原型ALLINI BI-D结合,分辨率为4.5 Å。这些结构揭示了与逃逸替代相关的三级结构扰动,这与其在体外形成异位ALLINI诱导聚合物的能力降低相关。这些发现提示了ALLINI耐药性的一般结构机制,并为改进ALLINIs的设计提供了见解。